Calgary, Alberta--(Newsfile Corp. - October 3, 2024) - Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF), a leader in portable NMR machines and MRI technology for industrial and research applications, is pleased to announce its participation at the upcoming Cantech Letter Investment Conference on Wednesday, October 9, 2024 in Toronto Ontario. Sean Krakiwsky, Chief Executive Officer of Nanalysis Scientific Corp. will be doing an investor presentation and participating in 1-on-1 meetings with investors at the conference.
2024 Cantech Letter Conference
Date: Wednesday, October 9, 2024
Location: Arcadian Loft, 8th floor, 401 Bay Street, Toronto, ON
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. to register
More info: https://www.cantechletter.com/conference/
Sean Krakiwsky , Chief Executive Officer of Nanalysis Scientific Corp. commented, “We are delighted to be participating in the Cantech Letter Conference as it’s an excellent platform to strengthen our connections within the capital markets. We hope to enhance our visibility, showcase our achievements, and increase our profile among the investor communities.”
About Cantech Letter Conference
The Cantech Letter Conference, recognized as Canada’s foremost technology investment event, provides up and coming technology companies with the unique opportunity to showcase their innovations and growth strategies, and participate in individual 1-on-1 meetings with potential investors and capital markets professionals. The conference serves as a hub for networking, knowledge exchange, and investment opportunities, while also featuring panel discussions with industry experts to offer insights into current trends, challenges, and opportunities within the technology sector.
About Nanalysis Scientific Corp.
About Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FSE: 1N1)Nanalysis Scientific Corp. in operates two primary business segments: Scientific Equipment and Security Services. Within its Scientific Equipment business is what the Company terms
For additional Information, please contact:
Matthew Selinger, Investor Relations
4155728152
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | C$0.37 |
| Daily Change: | -0.005 -1.35 |
| Daily Volume: | 33,888 |
| Market Cap: | C$41.270M |
November 21, 2024 October 22, 2024 August 28, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
